Evaluating the association between inflammatory markers and glycemic control status in type 2 diabetes mellitus patients: a tertiary care centre experience

Kavya Varshney; Mukul Singh; Sunil Ranga

doi:10.18203/2320-6012.ijrms20263379

Authors

Kavya Varshney Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
Mukul Singh Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
Sunil Ranga Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20263379

Keywords:

Diabetes mellitus, IL-6, IFN-γ, TNF-α, Ferritin, hs-CRP, HbA1c

Abstract

Background: Type 2 diabetes mellitus is a chronic, multifactorial metabolic disease in which systemic inflammation plays a key role in the pathogenesis of insulin resistance. This study aimed to compare serum concentrations of ferritin, hs-CRP, IL-6, TNF-α, and IFN-γ between type 2 diabetes mellitus patients and matched healthy controls, and to determine their correlation with glycated haemoglobin (HbA1c) and fasting insulin levels.

Methods: A case-control study was conducted comprising 50 patients with type 2 diabetes mellitus and 50 age- and sex-matched healthy controls under fasting conditions. Serum levels of HbA1c, fasting insulin, ferritin, hs-CRP, IL-6, TNF-α, and IFN-γ were measured. Intergroup comparisons were evaluated using the Mann–Whitney U test, and correlations with HbA1c and insulin were assessed using Spearman's rank correlation.

Results: Serum levels of ferritin, hs-CRP, IL-6, and TNF-α were significantly higher in type 2 diabetic patients than in healthy controls (p<0.001), whereas IFN-γ levels showed no significant intergroup difference (p=0.515). Serum ferritin demonstrated a statistically significant positive correlation with both HbA1c (rho=0.38, p=0.007) and fasting insulin (rho=0.33, p=0.021). In contrast, serum hs-CRP (rho=0.13, p=0.368 with HbA1c; rho=0.19, p=0.193 with insulin), IL-6 (rho=-0.01, p=0.952 with HbA1c; rho=-0.11, p=0.462 with insulin), TNF-α (rho=0.11, p=0.448 with HbA1c; rho=0.13, p=0.364 with insulin), and IFN-γ (rho=0.20, p=0.154 with HbA1c; rho=0.09, p=0.538 with insulin) showed no significant correlation with either HbA1c or fasting insulin levels (p>0.05).

Conclusions: Chronic systemic inflammation is pronounced in type 2 diabetes mellitus. Among the evaluated inflammatory biomarkers, serum ferritin uniquely correlates with both glycemic control and circulating insulin levels, highlighting its practical clinical utility in monitoring subclinical metabolic decompensation, while acute-phase cytokines reflect tonic inflammatory activation rather than direct glycemic fluctuations.

References

Powers AC, Niswender KD, Molina CE. Diabetes Mellitus: Diagnosis, Classification, and Pathophysiology. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 21st edition. New York: McGraw-Hill; 2018.

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88-98.

Barutta F, Bruno G, Grimaldi S, Gruden G. Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment. Endocrine. 2015;48:730-42.

Mankowska A, Pollak J, Sypniewska G. Association of C-reactive protein and other markers of inflammation with risk of complications in diabetic subjects. EJIFCC 2006;17:8-11.

Pfutzner A, Schondorf T, Hanefeld M, Forst T. High sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients. J Diabetes Sci Technol. 2010;4(3):706-16.

Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. J Am Coll Cardiol. 2005;11:4A-11A.

Amanullah S, Jarari A, Govindin M, Basha MI, Khateeja. Association of hs-CRP with diabetic and non-diabetic individuals. Jordan J Biol Sci. 2010;3(1):7-12.

American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Suppl 1):S14-31.

Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ. Textbook of diabetes. 5th edition. UK: Wiley Blackwell; 2016.

Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th edition. New Delhi: Saunders Harcourt; 2006.

Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113.

Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007;48(4):751-62.

Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ, Ye J. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem 2002;277(50):48115-21.

Zhang J. Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease. J Clin Invest 2007;117(4):871-3.

Mühl H, Pfeilschifter J. Anti-inflammatory properties of pro-inflammatory interferon-gamma. Int Immunopharmacol 2003;3(9):1247-55.

Ibarra Urizar A, Friberg J, Christensen DP, Lund Christensen G, Billestrup N. Inflammatory cytokines stimulate bone morphogenetic protein-2 expression and release from pancreatic beta cells. J Interferon Cytokine Res. 2016;36(1):20-9.

Son NE. Influence of ferritin levels and inflammatory markers on HbA1c in the type 2 diabetes mellitus patients. Pak J Med Sci. 2019;35:1030-5.

Sattar NA, Shaheen S, Sajid S. Association of bio-inflammatory markers (CRP, IL-6) with glucose level in obese T2DM Pakistani patients. JOP J Pancreas. 2018;19:282-6.

Malenica M, Silar M, Dujic T, Bego T, Semiz S, Skrbo S, et al. Importance of inflammatory markers and IL-6 for diagnosis and follow up of patients with type 2 diabetes mellitus. Med Glas (Zenica). 2017;14(2):169-75.

Shukaili AA, Al-Ghafri S, Al-Marhoobi S, Al-Abri S, Al-Lawati J, Al-Maskari M. Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol. 2013;2013:976810.